- Syngene International has entered into a strategic collaboration with Johns Hopkins University to advance early-stage drug discovery programmes and platform technologies.
- The partnership will be delivered through Syngene SynVent™ and its Connector model to support discovery, development and potential licensing opportunities.
Syngene International has announced a strategic collaboration with Johns Hopkins University to advance early-stage drug discovery programmes and technology platforms emerging from the university’s research laboratories. The collaboration will focus on translating academic discoveries into therapeutic candidates.
The partnership will be delivered through Syngene SynVent™, the company’s integrated drug discovery and development platform, which spans discovery biology, medicinal and synthetic chemistry, DMPK, toxicology and early development. Syngene will also deploy its Connector model, designed to link early-stage assets with strategic investors and downstream partnerships, to support research sponsorship and licensing opportunities.
According to Syngene, the collaboration aims to compress timelines for high-potential programmes and support their progression towards clinical relevance. The model is structured to integrate academic research capabilities with pharmaceutical, biotech and investor networks.
“We are delighted to be working with a renowned institution like Johns Hopkins. We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly compress the time required for high-potential programs to become clinically relevant, creating a faster and more efficient pipeline of new medicines.”
Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene International
Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, stated that the collaboration model is designed to connect discoveries from Johns Hopkins laboratories with Syngene’s drug discovery capabilities and industry partners, with the aim of advancing development programmes that could lead to new treatment options.
